Transforming growth factor beta-1 enhances cytotoxic effect of doxorubicin in human lung adenocarcinoma cells of A549 line

Cell Biology International

Volumn 31, Issue 8, 2007, Pages 851-855

  Filyak, Yevhen ^a,b   Filyak, Oksana ^a   Stoika, Rostyslav ^a  

^a INSTITUTE OF CELL BIOLOGY   (Ukraine)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

Apoptosis; Doxorubicin; Human lung adenocarcinoma A549 cells; TGFbeta 1

Indexed keywords

DOXORUBICIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL; CELL COUNT; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA;

ADENOCARCINOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG SYNERGISM; HUMANS; IMMUNOHISTOCHEMISTRY; POLY(ADP-RIBOSE) POLYMERASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34248574890     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2007.02.008     Document Type: Article

References (17)

1. Arcumone F., Animti F., Cuprunico G., and Lombardi P. New developments in antitumor anthracyclines. Pharmacol Ther 76 1-3 (1997) 117-124
2. Binaschi M., Capranico G., Dal Bo L., and Zunino F. Relationship between lethal effects and topoisomerase II mediated double-strand DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol 51 (1997) 1053-1059
3. Brown J.M., and Wouters B.J. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59 7 (1999) 1391-1399
4. Ciftci K., Su J., and Trovitch P.B. Growth factors and chemotherapeutic modulation of breast cancer cells. J Pharm Pharmacol 55 8 (2003 Aug) 1135-1141
5. Dubrovska A., Kanamoto T., Lomnytska M., Heldin C.H., Volodko N., and Souchelnytskyi S. TGB/Smad3 counteracts BRCA1-dependent repair of DNA damage. Oncogene 24 (2005) 2289-2297
6. Filyak O., and Stoika R. Comparative study of p53 expression in human carcinoma cell lines A549 and MCF7 under anticancer drug treatment. Ukr Biokhim Zh 77 2 (2005) 136-140
7. Harris A.L. DNA repair and resistance to chemotherapy. Cancer Surv 4 3 (1985) 601-624
8. Kanamoto T., Hellman U., Heldin C.H., and Souchelnytskyi S. Functional proteomics of transforming growth factor-β1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFβ1-dependent regulation of DNA repair. EMBO J 21 5 (2002) 1219-1230
9. Ewan K.B., Henshall-Powell R.L., Ravani S.A., Pajares M.J., Arteaga C., Warters R., et al. Transforming growth factor-1 mediates cellular response to DNA damage in situ. Cancer Res 62 (2002 October) 5627-5631
10. Koutsilieris M., Reyes-Moreno C., Choki I., Sourla A., Doillon C., and Pavlidis N. Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med 5 2 (1999 Feb) 86-97
11. Liang Y., Eid M.A., El Etreby F., Lewis R.W., and Kumar M.V. Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. Int J Oncol 21 6 (2002) 1259-1267
12. Massague J., Blain S., and Lo R. TGFβ signaling in growth control, cancer and heritable disorders. Cell 103 (2000) 295-309
13. van der Poel H.G., Hanrahan C., Zhong H., and Simons J.W. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30 6 (2003) 380-386
14. Puck T.T., and Marcus P.I. Clonal growth of mammalian cells in vitro; growth characteristics of colonies from single HeLa cells with and without a feeder layer. J Exp Med 103 2 (1956) 273-283
15. Souchelnytskyi S. Transforming growth factor-β signaling and its role in cancer. Exp Oncol 24 (2002) 3-12
16. Stoika R., Yakymovych M., Souchelnytskyi S., and Yakymovych I. Potential role of transforming growth factor beta 1 in drug resistance of tumor cells. Acta Biochim Pol 50 2 (2003) 497-508
17. Stoika R., Yakymovych M., Yakymovych I., and Chekhun V. Cisplatin-resistant derivatives of murine L1210 leukemia cells are not susceptible to growth-inhibiting and apoptosis-inducing actions of transforming growth factor-beta1. Anticancer Drugs 10 5 (1999) 457-463